Sökning: "overdiagnosis"
Visar resultat 1 - 5 av 13 avhandlingar innehållade ordet overdiagnosis.
1. Prostate Cancer Screening - Aspects of Overdiagnosis
Sammanfattning : The overall aim of this thesis is to explore aspects of overdiagnosis, i.e. the diagnosis of a tumor that in the absence of screening would never have been diagnosed, in prostate cancer (PC) screening. LÄS MER
2. Breast cancer screening with mammography of women 40-49 years in Sweden
Sammanfattning : Background The debate regarding the lower age limit for mammography service screening is old and lively; a product in part of the lower breast cancer risk in younger ages as well as the limited data available for studies of the younger age group. Recently the idea of inviting only high risk groups has gained momentum, however high risk might not be equivalent to greater benefit from screening. LÄS MER
3. Surveillance and follow-up of early prostate cancer
Sammanfattning : Active surveillance (AS) for prostate cancer was introduced to address overtreatment resulting from prostate-specific antigen (PSA) testing. Despite advancements such as Magnetic Resonance Imaging (MRI) and targeted biopsies, PSA remains crucial in prostate cancer diagnostics, leading to ongoing challenges of overdiagnosis and overtreatment. LÄS MER
4. The assessment of disease progression in keratoconus and corneal crosslinking in thin corneae
Sammanfattning : Keratoconus generally manifests in adolescents, and can progress leading to severely impaired vision. The risk of progression is inversely correlated to age; thus younger patients are at higher risk than older ones. Progressive keratoconus can be halted by corneal crosslinking (CXL). LÄS MER
5. Magnetic Resonance Imaging as a Screening Tool for Prostate Cancer
Sammanfattning : The overall aim of this thesis was to explore the role of Magnetic resonance imaging (MRI) of the prostate as an adjunct to the prostate-specific antigen (PSA)-test in screening for prostate cancer (PCa), focusing on the performance of MRI in detecting clinically significant PCa within the randomised controlled GÖTEBORG Prostate Cancer Screening 2 Trial. By inviting men 50–60 years of age to different screening strategies—PSA cut-off for biopsy 3. LÄS MER